HR Execs on the Move

Applied Micro Circuits Corporation

www.apm.com

 
AppliedMicro is a global leader in energy conscious computing and connectivity solutions for telco, enterprise, data center, consumer and SMB applications. With a 30-year heritage as an innovator in high-speed connectivity and high performance embedded processing, AppliedMicro employs patented transport and embedded processor SoCs to provide high performance energy efficient products. AppliedMicro`s corporate headquarters are located in Sunnyvale, California. Sales and engineering offices are located throughout the world.
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million
  • www.apm.com
  • 4555 Great America Pkwy Ste. 601
    Santa Clara, CA USA 95054
  • Phone: 408.542.8600

Executives

Name Title Contact Details

Similar Companies

A K Microsystems

A K Microsystems is a Richmond Hill, ON-based company in the Computers & Electronics sector.

Polar Semiconductor

Polar Semiconductor, Inc. is a Minneapolis, MN-based company in the Computers & Electronics sector.

Planar Monolithics Industries Inc

Planar Monolithics Industries Inc is a Frederick, MD-based company in the Computers and Electronics sector.

ZMD America

ZMD America is a Melville, NY-based company in the Computers and Electronics sector.

Xceleron

Xceleron believes that AMS technology and our expertise can get life-changing products (drugs and biobased) quickly and cost-effectively to people who need them.  We work with integrity and an open mind and are driven by science and the spirit of collaboration. Founded in 1997 in York, UK, and now headquartered in Germantown, Maryland, Xceleron pioneered human microdose and microtracer techniques using AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I, and Phase II/III clinical trials. Xceleron’s experience is especially valuable because the characteristics of many contemporary small molecules (low solubility, long half-life and disproportionate human metabolites) mean that their early pharmacokinetic and metabolic characterization is critical to the cost-effectiveness of clinical development.